Sector News

Sobi appoints Torbjorn Hallberg as general counsel

November 7, 2017
Life sciences

Swedish healthcare group Sobi has appointed Torbjorn Hallberg as its new general counsel and establishes a new leadership structure.

Hallberg, who joins from Takeda, where he served for seven years, first as senior director and corporate counsel and then more recently as its vice president, general counsel for emerging markets.

He arrives at Sobi will more than 15 years’ experience covering licensing, mergers and acquisitions at pharma groups such as Ferring and Nycomed.

Meanwhile, Sobi has also established a new leadership structure, consisting of chief executive officer Guido Oelkers, chief financial officer Mats-Olof Wallin, general counsel and head of legal affairs Carin Dahlquist (an acting role), head of EMENA Hege Hellström and head of North America Rami Levin.

Also sitting on the new team are Sobi’s head of specialty care Norbert Oppitz, head of medical and scientific affairs Armin Reininger, head of haemophilia Philip Wood and head of research and development and chief medical officer Milan Zdravkovic.

Source: PMLive

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach